4 - Two-Year Efficacy and Safety of Rezūm Water Vapor Thermal Therapy in Large Prostates (≥80 mL) Article Swipe

MAKE IMPACT

Mohannad Bitar , Déborah Jakubowicz , Roseanne Ferreira , Naeem Bhojani , Bilal Chughtai , Kevin C. Zorn , Luca Cindolo , G. Ferarri , Dean Elterman · YOU? · · 2025 · Open Access · · DOI: https://doi.org/10.1016/j.cont.2025.101928

Hypothesis / aims of study: While initial guidelines recommended Rezūm for prostates less than 80 mL, recent studies have demonstrated its efficacy and safety in larger prostates. Water Vapor Thermal Therapy (WVTT), Rezūm, is a minimally invasive therapy that uses water vapor to ablate benign prostatic tissue. This study aims to present the prospective, multi-center outcomes of the largest cohort of prostates ≥80 mL treated with Rezūm. Study design, materials and methods: This study involved a prospective, Rezum registry which collated information from two high-volume centers between April 2019 and August 2024. Baseline medical histories, uroflowmetry (Qmax, PVR), and validated questionnaires (IPSS, IPSS QoL, BPHII, IIEF-15, MSHQ-EjD) were recorded. The main outcomes assessed included symptom scores, functional improvement, and safety at baseline, 6, 12 and 24 months. Results: A total of 259 patients with a prostate volume ≥80 mL were treated with Rezūm. The median prostate volume was 105 mL (interquartile range 91–122.5 mL), with 207 patients (81.2%) exhibiting a median lobe. A history of urinary retention was noted in 86 patients (33.6%). On average, 13.2 injections (±3.8) were administered per procedure, which lasted an average of 6.9 minutes (±10.1). The IPSS improved from 21.8 (n=212) at baseline to 9.1 at 6 months (n=131), 6.6 at 12 months (n=107), and 5.7 at 24 months (n=68). At baseline, the maximum urinary flow rate (Qmax) was 8.2 mL/s (n=198), increasing to 14.6 mL/s at 6 months (n=45), 14.1 mL/s at 12 months (n=46), and 14.9 mL/s at 24 months (n=33). Post-void residual (PVR) volume at baseline was 132.5 mL (n=196), decreasing to 72 mL at 6 months (n=42), 60 mL at 12 months (n=93), and 90 mL at 24 months (n=38). The IPSS quality of life (IPSS QoL) score decreased from 4.5 (n=212) at baseline to 1.4 at 6 months (n=131), 1.65 at 12 months (n=107), and 1.1 at 24 months (n=68). The BPHII decreased from 7.5 at baseline (n=171) to 3.3 at 6 months (n=86), 2.9 at 12 months (n=65), and 2.3 at 24 months (n=35). There was no significant difference noted in sexual function as measured by IIEF and MSHQ. Interpretation of results: Rezūm water vapor therapy appears to be both effective and well-tolerated in men with significantly enlarged prostates (≥80 mL), including those with challenging anatomy such as a median lobe and those with a history of urinary retention. Symptom improvement was both rapid and sustained over time. The International Prostate Symptom Score (IPSS) improved from a baseline of 21.8 to 5.7 at 24 months. Maximum urinary flow rate (Qmax) also improved significantly, rising from 8.2 mL/s at baseline to 14.9 mL/s at 24 months. Similarly, post-void residual volume (PVR) decreased from 132.5 mL at baseline to 90 mL at 24 months. Quality of life, as assessed by the IPSS QoL score, also improved dramatically The BPH Impact Index (BPHII) followed a similar trend, decreasing from 7.5 to 2.3 by 24 months. Importantly, sexual function was preserved, with no significant changes observed in IIEF or MSHQ scores. Concluding message: These findings suggest that Rezūm is a promising minimally invasive treatment option even for patients with large prostates and complex anatomy, offering durable symptom relief without compromising sexual health. Significant improvements were observed in urinary symptoms and quality of life, with minimal impact on sexual function.Funding no funding Clinical Trial No Subjects Human Helsinki Yes Informed Consent Yes

Type

article

Language

en

Landing Page

https://doi.org/10.1016/j.cont.2025.101928

OA Status

gold

Related Works

10

OpenAlex ID

https://openalex.org/W4414159247

Raw OpenAlex JSON

OpenAlex ID

https://openalex.org/W4414159247

Canonical identifier for this work in OpenAlex

DOI

https://doi.org/10.1016/j.cont.2025.101928

Digital Object Identifier

Title

4 - Two-Year Efficacy and Safety of Rezūm Water Vapor Thermal Therapy in Large Prostates (≥80 mL)

Work title

Type

article

OpenAlex work type

Language

en

Primary language

Publication year

2025

Year of publication

Publication date

2025-01-01

Full publication date if available

Authors

Mohannad Bitar, Déborah Jakubowicz, Roseanne Ferreira, Naeem Bhojani, Bilal Chughtai, Kevin C. Zorn, Luca Cindolo, G. Ferarri, Dean Elterman

List of authors in order

Landing page

https://doi.org/10.1016/j.cont.2025.101928

Publisher landing page

Open access

Yes

Whether a free full text is available

OA status

gold

Open access status per OpenAlex

OA URL

https://doi.org/10.1016/j.cont.2025.101928

Direct OA link when available

Cited by

0

Total citation count in OpenAlex

Related works (count)

10

Other works algorithmically related by OpenAlex

Full payload